
|Videos|November 16, 2016
- NSCLC (Issue 11)
- Volume 4
- Issue 2
The Significance of Surgery Quality in NSCLC
Author(s)Raymond Osarogiagbon, MD
Raymond Osarogiagbon, MD, medical oncologist, Baptist Memorial Medical Group, discusses the significance of surgery quality in non-small cell lung cancer (NSCLC).
Advertisement
Articles in this issue
about 9 years ago
Erlotinib Plus Bevacizumab in EGFR-Mutant NSCLCabout 9 years ago
Clinical Trials Exploring Bevacizumab in NSCLCabout 9 years ago
Expert Explores Treatments for Biomarker-Negative Lung Cancerabout 9 years ago
Erlotinib/Bevacizumab Combo Warrants Consideration for EGFR+ NSCLCabout 9 years ago
Practice-Changing Translational Advances Predicted for NSCLCabout 9 years ago
Addressing the Challenges of Treating Non-Driver NSCLCAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















